之江生物(688317.SH):擬使用部分募集資金向子公司提供借款實施募投項目
格隆匯 1 月 25日丨之江生物(688317.SH)公佈,公司於2021年1月25日召開第四屆董事會第五次會議、第四屆監事會第二次會議審議通過了《關於使用部分募集資金向全資子公司提供借款實施募投項目的議案》,同意使用部分募集資金向全資子公司上海之江生物醫藥科技有限公司(“之江科技”)提供借款用於實施募投項目。
根據公司《首次公開發行股票並在科創板上市招股説明書》,公司募集資金投資項目“分子診斷工程研發中心建設項目”的實施主體為公司全資子公司上海之江生物醫藥科技有限公司,募集資金投資總額為22168.75萬元。為保障該募投項目的順利實施,公司擬以借款形式將22168.75萬元從募集資金專户劃轉至“分子診斷工程研發中心建設項目”募集資金專户。
公司募集資金投資項目“產品研發項目”的實施主體為之江科技和之江生物,募集資金投資總額為5.5億元,其中1.2億元為之江科技的募集資金投資總額。為保障該募投項目的順利實施,公司擬以借款形式將1.2億元募集資金從募集資金專户劃轉至“產品研發項目”募集資金專户。
上述借款期限為自實際借款之日起不超過3年,借款利率為無息。根據募集資金投資項目建設實際需要,到期後可續借或提前償還。本次借款僅限用於“分子診斷工程研發中心建設項目”和“產品研發項目”的實施,不得用作其他用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.